CA125 Detection Service

Creative Biolabs is a leading service provider that focuses on tumor-associated glycan detection. Based on our advanced platforms and extensive experience, now we provide the novel CA125 detection service for the diagnostic of ovarian cancer for our clients all over the world.

CA125 in Ovarian Cancer

For women, ovarian cancer is the fifth leading death of cancer death in the US. According to the statistics, takes approximately 7.6 million lives worldwide every year. As a disease of the ovaries, there are no obvious specific symptoms in the early stages of the disease until it has spread to organs other than the ovaries. When symptoms begin to manifest, computed tomography, a transvaginal ultrasound, or abdominal magnetic resonance imaging (MRI) are used to detect the ovaries and their possible external spread. In this case, protein-based testing using serum, blood, or urine samples has become an important early diagnosis method for ovarian cancer.

Studies have shown that more than 80-85% of women with epithelial ovarian cancer have elevated levels of CA125 in the serum. Therefore, the detection of serum levels of CA125 cancer antigen is a preliminary detection indicator for various types of cancer, including ovarian cancer. The level of CA-125 may be elevated in multiple types of cancer and a series of health conditions. As a type of tumor marker test, CA-125 detection is typically reserved for patients with suspected or confirmed ovarian cancer. In particular, CA-125 detection is always being used for diagnosing a pelvic mass, screening in high-risk patients, evaluating treatment response, estimating prognosis, as well as monitoring for cancer recurrence.

Conditions Cause an Elevated CA-125 Level

• Ovarian cancer
• Cancers of the pancreas, breast, and lung
• Uterine fibroids
• Pregnancy
• Liver disease
• Endometriosis
• Normal menstruation
• Pelvic inflammatory disease

Fig 1. Schematic of the sandwich immunoassay for CA125. (mAb-capture antibody; Ab-AP- alkaline phosphatase labeled detection antibody; antigen-CA125). (Al-Ogaidi, 2013)

Techniques for CA125 Detection in Ovarian Cancer

Based on the dual signal transduction mechanisms, an enzyme-linked immunosorbent assay (ELISA) has been developed for the detection of CA125 against ovarian cancer. Using both the Nano Electrode Array (NEA) chip and absorbance method, dual detection is possible. The NEA would be used to confirm the optical detection of CA125 in a high-binding 96-well plate. By labeling the detection antibody with alkaline phosphatase (AP), CA125 can be detected optically and electrochemically at the same time. 1.3 U/mL and 40 U/mL are the detection limits for optical and electrochemical immunoassays, respectively.

Creative Biolabs has been a long-term expert in the field of glycomics research. As a pioneer and the undisrupted global leader in tumor-associated glycan detection, we offer a variety of solutions to improve your productivity and streamline your research processes. If you are interested in our products or services, please do not hesitate to contact us for more detailed information.

Reference

1. Al-Ogaidi, I.; et al. Dual detection of cancer biomarker CA125 using absorbance and electrochemical methods. Analyst. 2013, 138(19): 5647-5653.

Related Services:

1. CA15-3 Detection Service
2. CA19-9 Detection Service
3. CA72-4 Detection Service
4. Prostate-specific Antigen (PSA) Detection Service
5. CEA Detection Service
6. Mucin Detection Service